Navigation Links
Elevated temperature enhances success of viral cancer therapy

A therapeutic approach for battling cancer that is based on infection with a specially designed virus similar to the one that causes the common cold has shown promise in clinical trials. Now, new research suggests that fever might be a useful weapon in the fight as well. The study, published in the July issue of Cancer Cell, demonstrates that tumor cells are even more sensitive to viral therapy after they have been incubated at an elevated temperature. The findings could have a significant impact on the future success of viral strategies for cancer therapy.

ONYX-015 is a mutated adenovirus that undergoes selective replication in tumor cells until the cells become so full of virus that they burst and die. The virus is modified so that it only copies itself in tumor cells and is safe for normal cells. In clinical trials, ONYX-015 was a successful therapy for many cancer patients, but the success varied considerably for reasons that were not well understood. Dr. Clodagh C. O'Shea and colleagues from the Cancer Research Institute at the University of California, San Francisco examined why ONYX-015 did not undergo replication in some cancer cells and if it might be possible to sensitize tumor cells to ONYX-015 therapy.

The researchers demonstrated that resistant tumor cells fail to complete an RNA export function that is necessary for ONYX-015 replication. Interestingly, when a cellular heat shock response was induced in the resistant tumor cells, either pharmacologically or by incubating the cells at an elevated temperature similar to that experienced by humans when they have a fever, the RNA export function was restored. Therefore, induction of the heat shock response could rescue ONYX-015 replication in resistant tumor cells.

According to Dr. O'Shea, "Our data suggest that a clinical strategy that does not advocate the use of pharmacological agents to suppress fever would favor the tumor-selective replication of ONYX-015. This study indicates th at induction of a heat shock response by pharmacological agents (that could potentially be administered systemically) or local hyperthermia, could greatly augment and broaden ONYX-015's clinical utility as a cancer therapy."

Clodagh C. O'Shea, Conrado Soria, Bridget Bagus, and Frank McCormick: "Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy" Publishing in Cancer Cell, Vol. 8, July 2005, pages 61-74 . DOI 10.1016/j.ccr.2005.06.009 www.cancercell.org


'"/>

Source:Cell Press


Related biology news :

1. Climate model links higher temperatures to prehistoric extinction
2. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
3. Ocean temperature predicts spread of marine species
4. Rising ocean temperatures, pollution have oysters in hot water
5. Healthy coral reefs hit hard by warmer temperatures
6. Pulsating ultrasound enhances gene therapy for tumors
7. NYU algorithm enhances ability to detect cancer genes
8. Proteasome activator enhances survival of Huntingtons disease neuronal model cells
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. Biomarkers isolated from saliva successfully predict oral and breast cancer
11. Secret of smallpoxs success may lead to bioterror cure
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... The number of ... past few years. More than 1,000 companies have been identified ... these are profiled in the report along with tabulation of ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. ... and assays, and their applicability in drug safety assessment, for the industry as ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court ... decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company ... DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary ...
(Date:1/14/2017)... Va. , Jan. 13, 2017  The Alliance ... statement in response to FDA final guidance ... for its continued leadership in emphasizing the importance of ... are keenly aware of the benefits biosimilars will bring ...   Yet the portion of the Guidance ...
Breaking Biology Technology: